Empowering the body’s natural defenses against life-threatening cancers.

T cell Antigen Coupler (TAC) Platform

Leveraging a T cell’s own recognition, activation and signaling properties.

Our proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.

Conquering new frontiers in cell therapy.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Pipeline & Programs

Building a robust pipeline of TAC-T cell therapies.

We are developing multiple TAC-based therapeutic candidates using both autologous and allogeneic manufacturing approaches. All programs leveraging our TAC technology have the potential for broad applicability across cancers with a high unmet need.

Recent News

September 12, 2022

Triumvira Immunologics Presents Initial HER2-Positive Solid …

September 10, 2022

A Phase I/II Trial Investigating Safety and Efficacy of Auto…

September 6, 2022

Triumvira Immunologics to Present Interim Clinical Data from…

September 12, 2022

Triumvira Immunologics Presents Initial HER2-Positive Solid …

September 10, 2022

A Phase I/II Trial Investigating Safety and Efficacy of Auto…

September 6, 2022

Triumvira Immunologics to Present Interim Clinical Data from…

Interested in learning more?